SCHEDULE 13G/A: Wasatch Advisors LP Discloses 6.6% Passive Stake in Sangamo Therapeutics
Beneficial Ownership Disclosure
Wasatch Advisors LP has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Sangamo Therapeutics, Inc. as of December 31, 2024.
Summary
- Wasatch Advisors LP reported beneficial ownership of 13,993,410 shares of Sangamo Therapeutics, Inc. Common Stock.
- This stake represents 6.6% of the total class of Sangamo Therapeutics, Inc. securities.
- Wasatch Advisors LP holds sole voting power and sole dispositive power over all 13,993,410 beneficially owned shares.
- This filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported ownership position.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sangamo Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake. It contains no positive or negative operational or financial news about the issuer, thus maintaining a neutral sentiment.
Positives
- The disclosure of a significant institutional investor, Wasatch Advisors LP, holding a substantial stake can be viewed as a vote of confidence in Sangamo Therapeutics, Inc.
- The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, suggesting a stable, passive investment.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.
Industry Context
This filing indicates continued institutional investment in Sangamo Therapeutics, a biotechnology company. Such disclosures are routine for significant passive stakes and reflect an investment firm's portfolio allocation decisions within the broader healthcare and life sciences sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 01/07/2025 | Date of filing of this Schedule 13G Amendment No. 7. |
Keywords
Sangamo Therapeutics, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.